Clozapine Reaction Shows Comparative Effectiveness In Transition
A recent study in The Lancet generated significant attention after showing much lower death rates for schizophrenia sufferers taking the cheap generic antipsychotic clozapine compared with branded drugs
You may also be interested in...
Pfizer's Record-Breaking $2.3 Bil. Settlement with DoJ Imposes New Restrictions on Corporate Behavior
A new corporate integrity agreement requires review of sales rep compensation structure, "needs assessment" of publications.
Three newly-approved drugs - Schering Plough's Saphris, Johnson & Johnson's Invega Sustenna and Vanda's Fanapt - are poised to enter the atypical antipsychotic space despite the crowd of approved products and the specter of market genericization
Shaking off stigma of life-threatening blood cell disorder will be almost impossible, says analyst.